Preparing for the End of the Biotech Bubble
The biotech bubble is here, and its end is coming -- eventually. Here are some ideas on how to handle it.
3 Companies at the Cutting Edge of Diabetes Research
No stones are gathering moss in the area of diabetes research. Eli Lilly, Merck, and MannKind are rolling ahead.
Biotech Investors: Be Careful Who You Listen To
When looking at buzz in the media about biotech companies, read and verify.
Meet the Most Bullish MannKind Investor. Ever.
Big hint: He named the company after himself.
What's MannKind Really Worth?
Overpriced? Undervalued? Priced about right? A look at how much MannKind is worth.
A Pharmacology Primer for Biotech Investors
Here's one way new investors can think about drug development.